Sugi Predict

Sugi Predict / Compounds / SCHEMBL85874

SCHEMBL85874

SCHEMBL85874

CC(C)(C)c1cc(NC(=O)CCCCN)c(SCCN)c(NC(=O)c2cccc(C(=O)Nc3cc(C(C)(C)C)cc(NC(=O)CCCCN)c3SCCN)c2)c1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 17/20 0.44
▸ HDAC1 Q13547 14/20 0.44
▸ KIF11 P52732 1/20 0.38
▸ HDAC2 Q92769 5/20 0.37
▸ NCOR2 Q9Y618 2/20 0.37
▸ HDAC4 P56524 3/20 0.37
▸ HDAC7 Q8WUI4 3/20 0.37
▸ HDAC10 Q969S8 3/20 0.37
▸ HDAC11 Q96DB2 3/20 0.37
▸ HDAC8 Q9BY41 3/20 0.37
▸ HDAC6 Q9UBN7 3/20 0.37
▸ HDAC9 Q9UKV0 3/20 0.37
▸ HDAC5 Q9UQL6 3/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL85871 0.97 HDAC3 (0.42) HDAC3HDAC1KIF11HDAC8HDAC6
SCHEMBL10198583 0.96 HDAC3 (0.41) HDAC3HDAC1MEN1KMT2A
SCHEMBL10198580 0.93 SMN1; SMN2 (0.41) HDAC3HDAC1KIF11MEN1KMT2A
SCHEMBL13057621 0.90 HDAC1 (0.38) HDAC3HDAC1KIF11HDAC2HDAC4
SCHEMBL19945148 0.90 HDAC3 (0.42) HDAC3HDAC1HDAC2NCOR2HDAC4
SCHEMBL85876 0.89 HDAC3 (0.47) HDAC3HDAC1HDAC2NCOR2HDAC4
SCHEMBL19940162 0.87 HDAC3 (0.40) HDAC3HDAC1HDAC2NCOR2HDAC4
SCHEMBL10198591 0.86 HDAC3 (0.45) HDAC3HDAC1HDAC2NCOR2HDAC4
SCHEMBL85827 0.86 KIF11 (0.41) KIF11HDAC8HDAC6MEN1KMT2A
SCHEMBL11927714 0.84 ERAP2 (0.42) KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10206894-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2019-02-19 — — US disclosed
US-9795575-B2 Compounds for use in treatment of mucositis INNOVATION PHARMACEUTICALS INC. (US) 2017-10-24 — — US disclosed
EP-2709619-B1 COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS CELLCEUTIX CORP (US) 2017-10-11 — — EP disclosed
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis INNOVATION PHARMACEUTICALS INC. 2017-08-10 — — US disclosed
US-9457027-B2 Compounds for use in treatment of mucostis CELLCEUTIX CORPORATION (US) 2016-10-04 — — US disclosed
US-20160213668-A1 Compounds for use in Treatment of Mucostis INNOVATION PHARMACEUTICALS INC. 2016-07-28 — — US disclosed
US-20160151314-A1 Facially Amphiphilic Polymers and Oligomers and Uses Thereof NATIONAL SCIENCE FOUNDATION 2016-06-02 — — US disclosed
US-9241917-B2 Facially amphiphilic polymers and oligomers and uses thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-01-26 — — US disclosed
US-9241917-B2 Facially amphiphilic polymers and oligomers and uses thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2016-01-26 — — US disclosed
US-9155738-B2 Compounds for use in treatment of mucostitis CELLCEUTIX CORPORATION (US) 2015-10-13 — — US disclosed
US-20100298344-A1 Polycationic Compounds And Uses Thereof POLYMEDIX, INC. 2010-11-25 — — US disclosed
US-20100298344-A1 Polycationic Compounds And Uses Thereof POLYMEDIX, INC. 2010-11-25 — — US disclosed
US-7745662-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2010-06-29 — — US disclosed
US-7745662-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2010-06-29 — — US disclosed
US-20090239811-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF POLYMEDIX, INC. (US) 2009-09-24 — — US disclosed
US-20090239811-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF POLYMEDIX, INC. (US) 2009-09-24 — — US disclosed
US-7553876-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2009-06-30 — — US disclosed
US-7553876-B2 Polycationic compounds and uses thereof POLYMEDIX, INC. (US) 2009-06-30 — — US disclosed
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT 2008-07-24 — — US disclosed
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof MIDCAP FINANCIAL SBIC, LP, AS ADMINISTRATIVE AGENT 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176807-A1 Facially amphiphilic polymers and oligomers and uses thereof TLR3, ABHD16A, ANTXR2 HDAC3 376/4885HDAC1 1308/4885KIF11 4373/4885
US-20170224640-A1 Compounds For Use In Treatment Of Mucositis MUC1, FUT6, MMP8 HDAC3 328/4885HDAC1 562/4885KIF11 2152/4885
US-20160151314-A1 Facially Amphiphilic Polymers and Oligomers and Uses Thereof TLR3, ABHD16A, ANTXR2 HDAC3 376/4885HDAC1 1308/4885KIF11 4373/4885
US-20100298344-A1 Polycationic Compounds And Uses Thereof VEGFA, VHL, PGF HDAC3 136/4885HDAC1 156/4885KIF11 3075/4885
US-10206894-B2 Compounds for use in treatment of mucositis MUC1, FUT6, SI HDAC3 291/4885HDAC1 405/4885KIF11 2804/4885
US-20090239811-A1 POLYCATIONIC COMPOUNDS AND USES THEREOF VEGFA, VHL, PGF HDAC3 136/4885HDAC1 156/4885KIF11 3075/4885
US-20160213668-A1 Compounds for use in Treatment of Mucostis MUC1, SOST, ALG1 HDAC3 912/4885HDAC1 1443/4885KIF11 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.